Update date
31 Dec 2020
Shareable Research Card
CYTOF - Altamira Therapeutics Ltd. Liabilities
This metric view shows CYTOF - Altamira Therapeutics Ltd. liabilities history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q4 2020
- Latest reported value
- CHF840,677
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Dec 2020
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q4 2020.
- Latest reported value on this page: CHF840,677.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Liabilities
Latest reported liabilities: CHF840,677. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q4 2020
SEC-backed company facts were refreshed from filings filed on 30 Apr 2025.
Benchmark Context
How Liabilities compares with peers
Altamira Therapeutics Ltd. sits in the bottom quarter of the current liabilities sample.
Compared with
Compared with 2 companies reporting liabilities in CHF. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0x the current sample midpoint. Liabilities is up about 19213% versus the comparable prior period.
- Visible rows currently span reported period ends from 31 Dec 2020 to 31 Dec 2023.
- Nearby companies in this sample: CREDIT SUISSE AG.
- Current sample position: rank #2 of 2 comparable companies.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
Altamira Therapeutics Ltd.: Liabilities
Latest period: Q4 2020. Period end: 31 Dec 2020. Units: CHF. Frequency: quarterly.
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
Metric Snapshot
- Latest value
- CHF840,677
- Coverage range
- 31 Dec 2018 - 31 Dec 2020
- Fact rows
- 3
What This Metric Tells You
- Shows reported liabilities over 31 Dec 2018 - 31 Dec 2020.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 3 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
- View Financial Facts Overview
- Altamira Therapeutics Ltd. SEC filings
- Latest 10-Q/10-K Hub
- Open SEC Company Facts
Direct filing link is shown only when a matched SEC filing document is available for this metric context.
Compare This Metric Across Companies
Compare latest available Liabilities levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
Altamira Therapeutics Ltd. appears at rank #2 in the latest comparison sample.
| Rank | Company | Latest value | Report period | Next step |
|---|---|---|---|---|
| 1 | CREDIT SUISSE AG (gldi) | CHF414,391,000,000 | Instant - 31 Dec 2023 | Open CREDIT SUISSE AG Liabilities |
| 2 | Altamira Therapeutics Ltd. (cytof) | CHF840,677 | Instant - 31 Dec 2020 | Open Altamira Therapeutics Ltd. Liabilities |
Metric Details
- Metric
- Liabilities (Liabilities)
- Frequency coverage
- quarterly
- Taxonomy
- us-gaap
- Units tracked
- CHF
- History range
- 31 Dec 2018 - 31 Dec 2020
- Facts on this page
- 3
- Metric definition
- Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
- SEC metric endpoint
- Open SEC company concept
Metric identity
1 identity field
Metric coverage
3 source fields
How to read it
1 detail
Source evidence
1 source field
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Liabilities, Quarterly (CHF)
Liabilities, YoY Quarterly Change (%)
Altamira Therapeutics Ltd. Quarterly Liabilities (CHF)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2020 | CHF840,677 | +CHF836,324 | +19213% | 31 Dec 2020 | 20-F | 31 Mar 2021 | 2020 | FY |
| Q4 2019 | CHF4,353 | -CHF2,106,375 | -100% | 31 Dec 2019 | 20-F | 31 Mar 2021 | 2020 | FY |
| Q4 2018 | CHF2,110,728 | -CHF17,877,753 | -89% | 31 Dec 2018 | 20-F | 31 Mar 2021 | 2020 | FY |
* marks a reported value that did not pass the local value check.